{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T15:51:25Z","timestamp":1769356285176,"version":"3.49.0"},"reference-count":21,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T00:00:00Z","timestamp":1703721600000},"content-version":"unspecified","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"James M. Anderson Center for Health Systems Excellence at Cincinnati Children's Hospital Medicl Center","award":["SEID19AB0"],"award-info":[{"award-number":["SEID19AB0"]}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["ALBON22QI0"],"award-info":[{"award-number":["ALBON22QI0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Qual"],"accepted":{"date-parts":[[2023,12,12]]},"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Cystic fibrosis (CF) is a systemic autosomal recessive condition characterised by progressive lung disease. CF pulmonary exacerbations (PEx) are episodes of worsening respiratory status, and frequent PEx are a risk factor for accelerated lung function decline, yet many people with CF (PwCF) go untreated at the time of decline. The goal of this quality improvement (QI) initiative was to improve recognition, treatment and follow-up of PEx in PwCF.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Using the Model for Improvement, the Cystic Fibrosis Learning Network (CFLN) initiated a QI innovation laboratory (iLab) with a global aim to decrease the rate of lung function decline in PwCF. The iLab standardised definitions for signals of PEx using a threshold for decline in forced expiratory volume in one second (FEV<jats:sub>1<\/jats:sub>) and\/or changes in symptoms. The FEV<jats:sub>1<\/jats:sub> decline signal was termed FIES (FEV<jats:sub>1<\/jats:sub>-indicated exacerbation signal). Processes for screening and recognition of FIES and\/or symptom changes, a treatment algorithm and follow-up in the presence of a signal were tested concurrently in multiple settings.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Specific aims<\/jats:title>\n                  <jats:p>The specific aim is to increase the per cent of PwCF assessed for a PEx signal at ambulatory encounters and to increase the per cent of recommendations to follow-up within 6 weeks for PwCF experiencing a PEx signal.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>FIES recognition increased from 18.6% to 73.4% across all teams during the iLab, and every team showed an improvement. Of PwCF assessed, 15.8% experienced an FIES event (&gt;10% decline in FEV<jats:sub>1<\/jats:sub> per cent predicted (FEV<jats:sub>1<\/jats:sub>pp)). Follow-up within 6 weeks was recommended for an average of 70.5% of those assessed for FIES and had an FEV<jats:sub>1<\/jats:sub>pp decline greater than 5%.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The CFLN iLab successfully defined and implemented a process to recognise and follow-up PEx signals. This process has the potential to be spread to the larger CF community. Further studies are needed to assess the impact of these processes on PwCF outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjoq-2023-002466","type":"journal-article","created":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T12:06:08Z","timestamp":1703765168000},"page":"e002466","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Improved recognition of lung function decline as signal of cystic fibrosis pulmonary exacerbation: a Cystic Fibrosis Learning Network Innovation Laboratory quality improvement initiative"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0385-7400","authenticated-orcid":false,"given":"Rhonda","family":"List","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Virginia School of Medicine, Charlottesville, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Solomon","sequence":"additional","affiliation":[{"name":"Pulmonary, Allergy, & Critical Care Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacy","family":"Bichl","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Pediatrics, Ann and Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bethany Jablonski","family":"Horton","sequence":"additional","affiliation":[{"name":"Public Health Sciences, University of Virginia, Charlottesville, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyi","family":"Shen","sequence":"additional","affiliation":[{"name":"Public Health Sciences, University of Virginia, Charlottesville, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bean","family":"Corcoran","sequence":"additional","affiliation":[{"name":"Connecticut Chapter, Cystic Fibrosis Foundation, Weston, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Sadeghi","sequence":"additional","affiliation":[{"name":"Pediatric Pulmonology and Sleep Medicine, Columbia University Irving Medical Center, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria T","family":"Britto","sequence":"additional","affiliation":[{"name":"Cincinnati Children's Hospital Medical Center James M Anderson Center for Health Systems Excellence, Cincinnati, Ohio, USA"},{"name":"University of Cincinnati College of Medicine, Cincinnati, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clement","family":"Ren","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Sleep Medicine, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9055-3247","authenticated-orcid":false,"given":"Dana","family":"Albon","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Virginia School of Medicine, Charlottesville, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,12,28]]},"reference":[{"key":"2025083110435775000_12.4.e002466.1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/153.4.345"},{"key":"2025083110435775000_12.4.e002466.2","unstructured":"Cystic fibrosis foundation patient Registry 2021 annual data report; 2022. Cystic fibrosis foundation Available: https:\/\/www.cff.org\/sites\/default\/files\/2021-11\/Patient-Registry-Annual-Data-Report.pdf"},{"key":"2025083110435775000_12.4.e002466.3","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.jcf.2019.05.009","article-title":"Correspondence between lung function and symptom measures from the cystic fibrosis respiratory symptom diary-chronic respiratory infection symptom score (CFRSD-CRISS)","volume":"18","author":"Gold","year":"2019","journal-title":"J Cyst Fibros"},{"key":"2025083110435775000_12.4.e002466.4","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jcf.2009.04.003","article-title":"Patient-reported respiratory symptoms in cystic fibrosis","volume":"8","author":"Goss","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"key":"2025083110435775000_12.4.e002466.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199409083311003"},{"key":"2025083110435775000_12.4.e002466.6","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jcf.2018.02.003","article-title":"Pulmonary exacerbations and acute declines in lung function in patients with cystic fibrosis","volume":"17","author":"Wagener","year":"2018","journal-title":"J Cyst Fibros"},{"key":"2025083110435775000_12.4.e002466.7","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200909-1421OC"},{"key":"2025083110435775000_12.4.e002466.8","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.21117"},{"key":"2025083110435775000_12.4.e002466.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2007.03.006"},{"key":"2025083110435775000_12.4.e002466.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2013.05.013"},{"key":"2025083110435775000_12.4.e002466.11","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.21442"},{"key":"2025083110435775000_12.4.e002466.12","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jcf.2018.06.003","article-title":"Impact of a program ensuring consistent response to acute drops in lung function in children with cystic fibrosis","volume":"17","author":"Schechter","year":"2018","journal-title":"J Cyst Fibros"},{"key":"2025083110435775000_12.4.e002466.13","doi-asserted-by":"crossref","DOI":"10.1002\/lrh2.10354","article-title":"Establishing a cystic fibrosis learning network: interventions to promote collaboration and data-driven improvement at scale","volume":"7","author":"Ong","year":"2023","journal-title":"Learn Health Syst"},{"key":"2025083110435775000_12.4.e002466.14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjoq-2022-001844","article-title":"Cystic fibrosis learning network Telehealth innovation lab during the COVID-19 pandemic: a success QI story for Interdisciplinary care and agenda setting","volume":"11","author":"Albon","year":"2022","journal-title":"BMJ Open Qual"},{"key":"2025083110435775000_12.4.e002466.15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jcf.2021.09.006","article-title":"Telehealth use in cystic fibrosis during COVID-19: association with race, Ethnicity, and socioeconomic factors","volume":"20 Suppl 3","author":"Albon","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2025083110435775000_12.4.e002466.16","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.12.004","article-title":"Factors associated with receiving CF care and use of Telehealth in 2020 among persons with cystic fibrosis in the United States","volume":"22","author":"Collaco","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2025083110435775000_12.4.e002466.17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jcf.2021.08.035","article-title":"Remote monitoring in Telehealth care delivery across the U.S. cystic fibrosis care network","volume":"20","author":"Ong","year":"2021","journal-title":"Journal of Cystic Fibrosis"},{"key":"2025083110435775000_12.4.e002466.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"2025083110435775000_12.4.e002466.19","doi-asserted-by":"crossref","unstructured":"Harris PA , Taylor R , Minor BL , et al . Redcap consortium, the Redcap consortium: building an international community of software partners. J Biomed Inform 2019;95. doi:10.1016\/j.jbi.2019.103208","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"2025083110435775000_12.4.e002466.20","first-page":"281","article-title":"CFTR Modulators: Transformative therapies for cystic fibrosis","volume":"27","author":"Dwight","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"key":"2025083110435775000_12.4.e002466.21","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1513\/AnnalsATS.202105-532OC","article-title":"Changes in care during the COVID-19 pandemic for people with cystic fibrosis","volume":"19","author":"Sanders","year":"2022","journal-title":"Ann Am Thorac Soc"}],"container-title":["BMJ Open Quality"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjoq-2023-002466","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T17:44:09Z","timestamp":1756662249000},"score":1,"resource":{"primary":{"URL":"https:\/\/qir.bmj.com\/lookup\/doi\/10.1136\/bmjoq-2023-002466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":21,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,12,28]]},"published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1136\/bmjoq-2023-002466"],"URL":"https:\/\/doi.org\/10.1136\/bmjoq-2023-002466","relation":{},"ISSN":["2399-6641"],"issn-type":[{"value":"2399-6641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12]]}}}